For people with mild-to-moderate acne, the 2022 top topical pairing was combined retinoid with benzoyl peroxide, with a 26% mean difference across 179 randomized trials. The British Journal of Dermatology network meta-analysis ranked it as the most effective topical pharmacological option.
But the useful takeaway for an adult counting down to a holiday party, work headshot, date, or family photo is not a promise about photo day. It is a realistic evidence checkpoint for active breakouts, redness, and visible acne spots.
At 1 week, lesion counts had already separated
A separate 2009 British Journal of Dermatology randomized acne trial studied 1,670 participants with acne vulgaris. Acne vulgaris is the common form of acne. The trial compared adapalene plus benzoyl peroxide with the corresponding monotherapies, meaning each active treatment used alone.
The 2009 trial reported significant differences in percentage lesion-count change as early as 1 week. Take an adult with chin breakouts and a work headshot on the calendar. The finding does not say their face changes by that date. It says the first measured separation between the pairing and single-ingredient options was 1 week.
Counted spots on skin made the early signal visible
The bridge from trial number to face-in-the-mirror worry is the lesion count. A lesion is an acne spot counted on the skin. The 2009 paper’s wording was that adapalene and benzoyl peroxide was “significantly more effective than corresponding monotherapies.”
Adults usually judge acne by what they can see: clogged-looking pores, inflamed bumps, and marks under bathroom light or a phone camera. In the same trial, the visible count was the measure with significant percentage change differences as early as 1 week.
Why did the later review matter?
The 2022 British Journal of Dermatology paper was a systematic review and network meta-analysis. In plain English, it compared many randomized controlled trials at once, including 179 RCTs of acne treatments and approximately 35 000 observations.
That broader design puts the 2009 timing result in context. One trial answered when the combination first separated on lesion counts. The later review answered where combined retinoid with benzoyl peroxide sat among topical pharmacological options for people with mild-to-moderate acne.
The 26% figure is a ranking result, not a personal forecast
The review reported the 26% mean difference with a 95% credible interval of 16·75–35·36%. A credible interval is a statistical range used in this kind of analysis to show uncertainty around the estimate.
For someone staring at a camera roll, the temptation is to treat 26% like a personal forecast. The British Journal of Dermatology review did not measure one adult’s selfie, one work headshot, or one date night. It ranked treatment categories across trials of mild-to-moderate acne.
The evidence side by side
The two British Journal of Dermatology sources answer different parts of the same practical question: which pairing ranked highest, and how early a trial saw lesion-count separation.
| Source and year | Who was measured | Main finding used here |
|---|---|---|
| British Journal of Dermatology, 2009 randomized trial | 1,670 participants with acne vulgaris | Adapalene plus benzoyl peroxide had significant lesion-count differences as early as 1 week |
| British Journal of Dermatology, 2022 network meta-analysis | People with mild-to-moderate acne in 179 randomized controlled trials and approximately 35 000 observations | Combined retinoid with benzoyl peroxide ranked as the most effective topical pharmacological option, with a 26% mean difference and a 95% credible interval of 16·75–35·36% |
What this means for you
If you are planning around photos, dates, or work events, treat 1 week as the earliest trial signal, not as a promise about your own skin. If you are considering adapalene, benzoyl peroxide, or a retinoid and benzoyl peroxide combination, ask a dermatologist or pharmacist how it fits your acne pattern.
You can also ask about irritation risk, other products you already use, and whether your breakouts are mild-to-moderate like the group in the 2022 review. The evidence supports the pairing’s ranking, but how to use any treatment is a personal medical question.